Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arvind Mathur

Showing results (121-130 of 148) with videos related to

Pageof 15
Sort By:
ACS Medicinal Chemistry Letters|June 20, 2020
Discovery of BMS-986251: A Clinically Viable, Potent, and Selective RORγt Inverse AgonistRobert J Cherney, Lyndon A M Cornelius, Anurag Srivastava, et al.
Journal of Medicinal Chemistry|September 19, 2023
Discovery of <b>12</b> (BMS-986172) as a Highly Potent MGAT2 Inhibitor that Achieved Targeted Efficacious Exposures at a Low Human Dose for the Treatment of Metabolic DisordersWei Meng, Robert Brigance, James Mignone, et al.
Journal of Medicinal Chemistry|December 23, 2016
Asymmetric Hydroboration Approach to the Scalable Synthesis of ((1R,3S)-1-Amino-3-((R)-6-hexyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (BMS-986104) as a Potent S1P<sub>1</sub> Receptor ModulatorMichael G Yang, Zili Xiao, T G Murali Dhar, et al.
Journal of Medicinal Chemistry|November 23, 2020
Discovery of BMS-986144, a Third-Generation, Pan-Genotype NS3/4A Protease Inhibitor for the Treatment of Hepatitis C Virus InfectionLi-Qiang Sun, Eric Mull, Stanley D'Andrea, et al.
ACS Medicinal Chemistry Letters|August 20, 2015
Discovery of a Highly Selective JAK2 Inhibitor, BMS-911543, for the Treatment of Myeloproliferative NeoplasmsHonghe Wan, Gretchen M Schroeder, Amy C Hart, et al.
ACS Medicinal Chemistry Letters|November 20, 2020
Driving Potency with Rotationally Stable Atropisomers: Discovery of Pyridopyrimidinedione-Carbazole Inhibitors of BTKAnurag S Srivastava, Soo Ko, Scott H Watterson, et al.
Bioorganic & Medicinal Chemistry Letters|February 12, 2014
Identification of 1-{2-[4-chloro-1'-(2,2-dimethylpropyl)-7-hydroxy-1,2-dihydrospiro[indole-3,4'-piperidine]-1-yl]phenyl}-3-{5-chloro-[1,3]thiazolo[5,4-b]pyridin-2-yl}urea, a potent, efficacious and orally bioavailable P2Y(1) antagonist as an antiplatelet agentYoon T Jeon, Wu Yang, Jennifer X Qiao, et al.
Journal of Medicinal Chemistry|May 24, 2025
Discovery and Characterization of a First-in-Class LIV1-TLR7/8 Immunomodulatory Conjugate with Robust Myeloid Activation and Antitumor ActivitySayumi Yamazoe, Yam Poudel, Emanuela Sega, et al.
ACS Medicinal Chemistry Letters|May 26, 2015
Discovery of Clinical Candidate BMS-906024: A Potent Pan-Notch Inhibitor for the Treatment of Leukemia and Solid TumorsAshvinikumar V Gavai, Claude Quesnelle, Derek Norris, et al.
Journal of Medicinal Chemistry|October 6, 2021
Screening Hit to Clinical Candidate: Discovery of BMS-963272, a Potent, Selective MGAT2 Inhibitor for the Treatment of Metabolic DisordersHuji Turdi, Hannguang Chao, Jon J Hangeland, et al.
Pageof 15

Showing results (121-130 of 148) with videos related to

Sort By:
Pageof 15
ACS Medicinal Chemistry Letters|June 20, 2020
Discovery of BMS-986251: A Clinically Viable, Potent, and Selective RORγt Inverse AgonistRobert J Cherney, Lyndon A M Cornelius, Anurag Srivastava, et al.
Journal of Medicinal Chemistry|September 19, 2023
Discovery of <b>12</b> (BMS-986172) as a Highly Potent MGAT2 Inhibitor that Achieved Targeted Efficacious Exposures at a Low Human Dose for the Treatment of Metabolic DisordersWei Meng, Robert Brigance, James Mignone, et al.
Journal of Medicinal Chemistry|December 23, 2016
Asymmetric Hydroboration Approach to the Scalable Synthesis of ((1R,3S)-1-Amino-3-((R)-6-hexyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (BMS-986104) as a Potent S1P<sub>1</sub> Receptor ModulatorMichael G Yang, Zili Xiao, T G Murali Dhar, et al.
Journal of Medicinal Chemistry|November 23, 2020
Discovery of BMS-986144, a Third-Generation, Pan-Genotype NS3/4A Protease Inhibitor for the Treatment of Hepatitis C Virus InfectionLi-Qiang Sun, Eric Mull, Stanley D'Andrea, et al.
ACS Medicinal Chemistry Letters|August 20, 2015
Discovery of a Highly Selective JAK2 Inhibitor, BMS-911543, for the Treatment of Myeloproliferative NeoplasmsHonghe Wan, Gretchen M Schroeder, Amy C Hart, et al.
ACS Medicinal Chemistry Letters|November 20, 2020
Driving Potency with Rotationally Stable Atropisomers: Discovery of Pyridopyrimidinedione-Carbazole Inhibitors of BTKAnurag S Srivastava, Soo Ko, Scott H Watterson, et al.
Bioorganic & Medicinal Chemistry Letters|February 12, 2014
Identification of 1-{2-[4-chloro-1'-(2,2-dimethylpropyl)-7-hydroxy-1,2-dihydrospiro[indole-3,4'-piperidine]-1-yl]phenyl}-3-{5-chloro-[1,3]thiazolo[5,4-b]pyridin-2-yl}urea, a potent, efficacious and orally bioavailable P2Y(1) antagonist as an antiplatelet agentYoon T Jeon, Wu Yang, Jennifer X Qiao, et al.
Journal of Medicinal Chemistry|May 24, 2025
Discovery and Characterization of a First-in-Class LIV1-TLR7/8 Immunomodulatory Conjugate with Robust Myeloid Activation and Antitumor ActivitySayumi Yamazoe, Yam Poudel, Emanuela Sega, et al.
ACS Medicinal Chemistry Letters|May 26, 2015
Discovery of Clinical Candidate BMS-906024: A Potent Pan-Notch Inhibitor for the Treatment of Leukemia and Solid TumorsAshvinikumar V Gavai, Claude Quesnelle, Derek Norris, et al.
Journal of Medicinal Chemistry|October 6, 2021
Screening Hit to Clinical Candidate: Discovery of BMS-963272, a Potent, Selective MGAT2 Inhibitor for the Treatment of Metabolic DisordersHuji Turdi, Hannguang Chao, Jon J Hangeland, et al.
Pageof 15